Switch theme
Sign up to access all valuation multiples
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
1971
210
LTM Revenue $5.4M
Last FY EBITDA -$36.2M
$57.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Veru has a last 12-month revenue (LTM) of $5.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Veru achieved revenue of $16.9M and an EBITDA of -$36.2M.
Veru expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Veru valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.4M | XXX | $16.9M | XXX | XXX | XXX |
| Gross Profit | $1.8M | XXX | $5.9M | XXX | XXX | XXX |
| Gross Margin | 32% | XXX | 35% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$36.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -214% | XXX | XXX | XXX |
| EBIT | -$40.1M | XXX | -$38.1M | XXX | XXX | XXX |
| EBIT Margin | -736% | XXX | -226% | XXX | XXX | XXX |
| Net Profit | -$35.9M | XXX | -$37.8M | XXX | XXX | XXX |
| Net Margin | -659% | XXX | -224% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Veru's stock price is $1.
Veru has current market cap of $74.5M, and EV of $57.9M.
See Veru trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $57.9M | $74.5M | XXX | XXX | XXX | XXX | $-0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Veru has market cap of $74.5M and EV of $57.9M.
Veru's trades at 3.5x EV/Revenue multiple, and -0.8x EV/EBITDA.
Equity research analysts estimate Veru's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Veru has a P/E ratio of -2.1x.
See valuation multiples for Veru and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $74.5M | XXX | $74.5M | XXX | XXX | XXX |
| EV (current) | $57.9M | XXX | $57.9M | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.8x | XXX | XXX | XXX |
| EV/EBIT | -1.4x | XXX | -1.5x | XXX | XXX | XXX |
| EV/Gross Profit | 32.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | -2.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVeru's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Veru's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Veru's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Veru and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 261% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Veru acquired XXX companies to date.
Last acquisition by Veru was XXXXXXXX, XXXXX XXXXX XXXXXX . Veru acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Veru founded? | Veru was founded in 1971. |
| Where is Veru headquartered? | Veru is headquartered in United States of America. |
| How many employees does Veru have? | As of today, Veru has 210 employees. |
| Who is the CEO of Veru? | Veru's CEO is Dr. Mitchell S. Steiner, F.A.C.S.,M.D.. |
| Is Veru publicy listed? | Yes, Veru is a public company listed on NAS. |
| What is the stock symbol of Veru? | Veru trades under VERU ticker. |
| When did Veru go public? | Veru went public in 1990. |
| Who are competitors of Veru? | Similar companies to Veru include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Veru? | Veru's current market cap is $74.5M |
| What is the current revenue of Veru? | Veru's last 12 months revenue is $5.4M. |
| What is the current EV/Revenue multiple of Veru? | Current revenue multiple of Veru is 10.6x. |
| Is Veru profitable? | Yes, Veru is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
